Assembly Biosciences ASMB Increase Decrease In Accrued Research And Development Expenses
Increase Decrease In Accrued Research And Development Expenses at other companies
Other financials
Where this comes from
Reported directly by Assembly Biosciences in its filing.
Tagged under the XBRL concept asmb:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses.
The official record: Assembly Biosciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Assembly Biosciences's increase decrease in accrued research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Assembly Biosciences's increase decrease in accrued research and development expenses?
- Assembly Biosciences (ASMB) reported increase decrease in accrued research and development expenses of -$849K in Q1 2026.
- How has Assembly Biosciences's increase decrease in accrued research and development expenses changed year-over-year?
- Assembly Biosciences's increase decrease in accrued research and development expenses decreased by 408.4% year-over-year, from -$167K to -$849K.
- What is the long-term trend for Assembly Biosciences's increase decrease in accrued research and development expenses?
- Over 2 years (2021 to 2023), Assembly Biosciences's increase decrease in accrued research and development expenses has grown at a 41.8% compound annual growth rate (CAGR), from -$1.11M to -$2.24M.
- What does increase decrease in accrued research and development expenses mean?
- This represents the change in liabilities related to research and development activities that have been incurred but not yet paid in cash. An increase indicates that the company is deferring cash outflows for R&D, while a decrease indicates the settlement of these obligations. For a clinical-stage biotech, this is a critical indicator of R&D spending momentum and working capital management.